Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer

Abstract

The results suggest that trastuzumab as adjuvant therapy for early breast cancer may be cost effective when given over either 52 or 9 weeks at current acquisition costs in Australia. However, the overall budget impact of the 52-week course is significant, and the 9-week course appears economically attractive.

Custo-efetividade de um programa de rastreamento organizado de câncer de mama no Sul do Brasil

“…Foram encontrados cinco estudos relevantes, um deles comparando diferentes estadiamentos e os demais avaliando somente pacientes com estadiamentos precoces ou tardios 20,21,22,23,24 . Após a avaliação crítica desses estudos, definiu-se os valores mostrados na Tabela 1.…”

Efficacy of Primed In Situ Labelling in Determination of HER-2 Gene Amplification and CEN-17 Status in Breast Cancer Tissue

“…Trastuzumab adjuvant treatment for early HER-2 positive breast cancer is effective for improving patient survival and cost-effectiveness analyses of such treatment have shown acceptable ratios (Fagnani et al, 2007;Garrison et al, 2007;Millar and Millward, 2007;Norum et al, 2007). However, there is a negative aspect to trastuzumab therapy, namely cardiac toxicity (Wolff et al, 2007), which is possibly due to myocardial HER-2 gene over-expression associated with anthracycline treatment (De Korte et al, 2007) and substantial trastuzumab therapy 330 costs.…”

Bridging Trial and Decision: A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions

“…A total of 11 publications met the inclusion criteria [37][38][39][40][41][42][43][44][45][46][47]. All studies used decision-analytic modeling.…”

“…Seven studies compared one trastuzumab regimen to care as usual [38,39,41,44 -47]. Two studies combined data from different trastuzumab regimens into one intervention that was compared to care as usual [42,44]. More than one trastuzumab regimen was considered by four studies [37,40,42,43].…”

“…Two studies combined data from different trastuzumab regimens into one intervention that was compared to care as usual [42,44]. More than one trastuzumab regimen was considered by four studies [37,40,42,43]. In these studies the different trastuzumab regimens were all compared to care as usual, which means that they did not calculate the cost-effectiveness of one strategy to the next best strategy.…”